BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

967 related articles for article (PubMed ID: 18304898)

  • 1. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.
    Al Hadithy AF; de Boer NK; Derijks LJ; Escher JC; Mulder CJ; Brouwers JR
    Dig Liver Dis; 2005 Apr; 37(4):282-97. PubMed ID: 15788214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
    Gearry RB; Barclay ML; Roberts RL; Harraway J; Zhang M; Pike LS; George PM; Florkowski CM
    Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
    Hindorf U; Lyrenäs E; Nilsson A; Schmiegelow K
    Scand J Gastroenterol; 2004 Nov; 39(11):1105-12. PubMed ID: 15545169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thioguanine nucleotides and thiopurine methyltransferase in immunobullous diseases: optimal levels as adjunctive tools for azathioprine monitoring.
    el-Azhary RA; Farmer SA; Drage LA; Rogers RS; McEvoy MT; Davis MD; Bridges AG; Gibson LE
    Arch Dermatol; 2009 Jun; 145(6):644-52. PubMed ID: 19528417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.
    Gilissen LP; Bierau J; Derijks LJ; Bos LP; Hooymans PM; van Gennip A; Stockbrügger RW; Engels LG
    Aliment Pharmacol Ther; 2005 Oct; 22(7):605-11. PubMed ID: 16181300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.
    González-Lama Y; Bermejo F; López-Sanromán A; García-Sánchez V; Esteve M; Cabriada JL; McNicholl AG; Pajares R; Casellas F; Merino O; Carpio D; Vera MI; Muñoz C; Calvo M; Benito LM; Bujanda L; García-Fernández FJ; Ricart E; Ginard D; Velasco M; Carneros JA; Manceñido N; Calvo M; Algaba A; Froilan C; Cara C; Maté J; Abreu L; Gisbert JP;
    Aliment Pharmacol Ther; 2011 Sep; 34(5):544-54. PubMed ID: 21722149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.
    Hindorf U; Lindqvist M; Hildebrand H; Fagerberg U; Almer S
    Aliment Pharmacol Ther; 2006 Jul; 24(2):331-42. PubMed ID: 16842460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease.
    Herrlinger KR; Fellermann K; Fischer C; Kreisel W; Deibert P; Schoelmerich J; Fleig WE; Ruhl A; Reinshagen M; Greinwald R; Stange EF; Schwab M
    Aliment Pharmacol Ther; 2004 Jun; 19(12):1269-76. PubMed ID: 15191508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: thiopurines in inflammatory bowel disease.
    Derijks LJ; Gilissen LP; Hooymans PM; Hommes DW
    Aliment Pharmacol Ther; 2006 Sep; 24(5):715-29. PubMed ID: 16918876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
    Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
    Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations in patients with chronic inflammatory diseases.
    Schedel J; Gödde A; Schütz E; Bongartz TA; Lang B; Schölmerich J; Müller-Ladner U
    Ann N Y Acad Sci; 2006 Jun; 1069():477-91. PubMed ID: 16855176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment.
    van Egmond R; Chin P; Zhang M; Sies CW; Barclay ML
    Aliment Pharmacol Ther; 2012 May; 35(10):1181-9. PubMed ID: 22486532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of inosine-5'-monophosphate dehydrogenase in thiopurine metabolism in patients with inflammatory bowel disease.
    Haglund S; Vikingsson S; Söderman J; Hindorf U; Grännö C; Danelius M; Coulthard S; Peterson C; Almer S
    Ther Drug Monit; 2011 Apr; 33(2):200-8. PubMed ID: 21311411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
    Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines.
    Waljee AK; Joyce JC; Wang S; Saxena A; Hart M; Zhu J; Higgins PD
    Clin Gastroenterol Hepatol; 2010 Feb; 8(2):143-50. PubMed ID: 19835986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center.
    Banerjee S; Bishop WP
    J Pediatr Gastroenterol Nutr; 2006 Sep; 43(3):324-30. PubMed ID: 16954954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.